Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Non-muscle-invasive bladder cancer

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

- PMLiVE

J&J gets pharma Q2 results off to a flying start

OTC recovery and Synthes acquisition help boost sales performance

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

- PMLiVE

Boehringer breaks into oncology with FDA approval

Agency backs company's first cancer drug afatinib in lung cancer

- PMLiVE

J&J files ‘breakthrough’ drug ibrutinib in US

FDA to assess drug in lymphoma and leukaemia

- PMLiVE

GSK signs $500m-plus technology deal with Immunocore

Will make use of ImmTAC technology to activate immune system to kill cancerous or infected cells

- PMLiVE

GSK files combination skin cancer drug in US

Seeks FDA approval for Tafinlar - Mekinist combination in melanoma

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

- PMLiVE

FDA grants orphan status to Activartis’ brain cancer immunotherapy

Regulator says AV0113 has potential in rare cancer malignant glioma

- PMLiVE

Roche’s Perjeta on US fast-track for early breast cancer

FDA grants priority review for drug's use before surgery

- PMLiVE

Merck Serono pushes into immunotherapies for cancer

Pharma company sets up dedicated R&D unit

Bayer symbol

Bayer signs $520m cancer alliance with Seattle Genetics

Will focus on development of antibody-drug conjugates

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links